Restless Leg Syndrome in Patients on Hemodialysis Around Rize

Yıl 2015, Cilt: 17 Sayı: 3, 99 - 101, 01.12.2015

Osman Zikrullah Şahin Ahmet Tüfekçi Serkan Kırbaş Serap Baydur Şahin Özlem Bilir Teslime Ayaz

Öz

Aim: Our aim was to determine the prevalence of restless leg syndrome (RLS) in patients onhemodialysis in Rize and to compare the demographic and biochemical characteristics in patientswith and without RLS.Method: We enrolled all the patients over 18 years of age who were on hemodialysis for atleast three months between April and June 2014 in five dialysis centers in Rize. RLS patients’diagnoses were confirmed using the The International Restless Legs Syndrome Study Group(IRLSSG) criteria. Age, duration of hemodialysis, presence of diabetes, hemoglobin andhematocrit values, serum levels of urea, creatinine, sodium, potassium, calcium, phosphor,glucose, albumin, uric acid, iron, iron binding capacity, ferritin, and parathyroid hormone (PTH)were recorded.Results: 148 patients (43,2% female) were included in this study. The mean age of patients was61.00 ± 14,9 years . The mean duration of hemodialysis was 49,47 ± 67,3 months (4552). RLS was detected in 50 patients (33,7%). While the ratio of patients with diabetes was58% in RLS group, this ratio was 32,7% in RLS negative group (p= 0.003). Levels of fastingplasma glucose were significantly different in the two groups (151,40 ± 81.81 vb 116,00 ± 57.22,p= 0.003). While 58% of patients with RLS were female, this ratio was 35,7% in patients withoutRLS (p= 0.014). PTH, C-reactive protein, calcium, phosphorus, albumin, iron, iron bindingcapacity and ferritin levels were similar in the two groups.Conclusion: We found a 33.7% prevalence of RLS in patients receiving hemodialysis treatmentand the ratio of diabetes and female genderwere higher in patients with RLS

Anahtar Kelimeler

Restless leg syndrome, hemodialysis

RİZE BÖLGESİNDE HEMODİYALİZE GİREN HASTALARDA HUZURSUZ BACAK SENDROM SIKLIĞI VE İLİŞKİLİ FAKTÖRLER

Öz

Amaç: Çalışmanın amacı; Rize ilinde hemodiyalize giren hastalarda Huzursuz bacak sendromu(HBS) sıklığını saptamak ve HBS olan ve olmayan hastalar arasındaki demografik vebiyokimyasal göstergeleri karşılaştırmaktır.Yöntem: Bu çalışmaya Nisan-Haziran 2014 tarihleri arasında Rize ve ilçelerinde bulunan 5hemodiyaliz merkezinde en az üç aydır hemodiyalize giren 18 yaş üstündeki tüm hemodiyalizhastaları alındı. HBS tanısı için uluslararası HBS çalışma grubu (The International RestlessLegs Syndrome Study Group) tarafından belirlenen tanı kriterleri kullanıldı Hastaların yaşı,diyaliz tedavi süreleri, diyabet varlığı, hemoglobin, hematokrit, serum üre, kreatinin, sodyum,potasyum, kalsiyum, fosfor, glukoz, albümin, ürik asit, demir, total demir bağlama kapasitesi,ferritin ve parathormon düzeyleri kaydedildi.Bulgular: Çalışmaya 64’ü kadın (% 43,2) toplam 148 hasta dâhil edildi. Hastaların ortalamayaşı 61.00 ± 14,9 yıldı . Ortalama hemodiyaliz süresi 49,47 ± 67,3 aydı (4-552 ay). 50(% 33,7) hastada HBS saptandı. HBS olan grupta diyabetik hasta oranı % 58 iken, olmayangrupta bu oran % 32,7 idi (p= 0.003). Açlık kan şekeri seviyeleri de iki grup arasında anlamlıfarklılık gösteriyordu (151,40 ± 81.81’ e 116,00 ± 57.22, p= 0.003).HBS olan hastaların % 58’ikadın iken HBS olmayan grupta bu oran % 35,7 olarak bulundu (p= 0.014). Parathormon, Creaktif protein, kalsiyum, fosfor, albümin, demir, ferritin ve transferrinsaturasyonu oranları heriki grupta benzerdi.Sonuç: Bu çalışmada hemodiyalize giren hastalarda HBS sıklığı %33.7 olarak saptandı vediyabet ve kadın cinsiyet oranı HBS olan grupta daha fazlaydı

Anahtar Kelimeler

Huzursuz bacak sendromu, hemodiyaliz

Kaynakça

• Aksu M. Restless Legs Syndrome. Türkiye Klinikleri J Int Med Sci. 2007,3;44-7.
• Castillo PR, Kaplan J, Lin SC, et al. Prevalence of restless legs syndrome among native South Americans residing in coastal and mountainous areas. Mayo Clin Proc 2006; 81: 1345-7.
• Symvoulakis E, Anyfantakis D, Lionis C. Restless legs syndrome: literature review. Sao Paulo Med J 2010; 128: 167- 70.
• Colin Quinn, Mateen Uzbeck, Imran Saleem and et al. Iron status and chronic kidney disease predict restless legs syndrome in an older hospital population. Sleep Medicine 2011;12: 295–301.
• Berger K, Luedemann J, Trenkwalder C, et al. Sex and the risk of restless leg syndrome in the general population. Arch Intern Med 2004; 164: 196-202.
• Bhowmik D, Bhatia M, Gupta S, Agarwal S, Tiwari S, Dash S. Restless leg syndrome in uremic patients on hemodialysis. Am J Kidney Dis. 2003; 41: 833-9.
• Kutner N, Bliwisw D. Restless leg complaint in African American and Caucasian hemodialysis patients. Sleep Med. 2002; 3: 497-500.
• Yasemin Soyoral, Hayriye Sayarlıoğlu, Deniz Tuncel et al. Prevalence and risk factors of restless leg syndrome in a single hemodialysis unit. Turk J Med Sci 2010; 40 (3): 443- 446.
• Mithat Bedir, Ayșe Jini Güneș, Havva Cilan et al. Restless Legs Syndrome in End Stage Chronic Renal Failure Patients Receiving Hemodialysis Treatment. Kafkas J Med Sci 2013; 3(2):62–67.
• Berger K, Kurth T. RLS epidemiology--frequencies, risk factors and methods in population studies. Mov Disord 2007; 22: 420-3.
• Yuksel S, Colbay M, Yaman M, Uslan I, Acarturk G, Karaman O. Evaluation of diagnostic criteria of restless leg syndrome in hemodialysis patients. Eur J Gen Med. 2007; 4: 145-8.
• Suber Dıkıcı, Anzel Bahadır, Davut Baltacı, et al. Association of anxiety, sleepiness, and sexual dysfunction with restless legs syndrome in hemodialysis patients. Hemodialysis International 2014; 18:809–818.
• Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165: 1286-92.
• Kim JM, Kwon HM, Lim CS, et al. Restless Leg syndrome in Patients on Hemodialysis: Symptom Severity and Risk Factors. J Clin Neurol 2008; 4: 153-7.
• Harris DC, Chapman JR, Stewart JH, Lawrence S, Roger SD. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med. 1991; 21: 693-700.
• Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A. double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis. 2004; 43: 663-70.
• Collado-Seidel V, Kohnen R, Samtleben W, Hillebrand GF, Oertel WH, Trenkwalder C. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis. 1998; 31: 324-8.
• Miranda M, Araya F, Castillo JL, Durán C, González F, Arís L. Restless legs syndrome: a clinical study in adult general population and in uremic patients. Rev Med Chil. 2001; 129:179-86.